10-K: Cytek Biosciences Reports FY2024 Results: Revenue Growth Amidst Internal Control Challenges

Cytek Biosciences announces a 4% increase in revenue for fiscal year 2024, reaching $200.5 million, while addressing material weaknesses in internal control over financial reporting.

Summary

• Cytek Biosciences reported a revenue increase of 4% for fiscal year 2024, with total revenue reaching $200.5 million compared to $193.0 million in 2023.
• The company experienced a net loss of $6.0 million in 2024, an improvement from the $12.1 million net loss in 2023.
• Cash, cash equivalents, and short-term investments totaled $277.9 million as of December 31, 2024.
• The company identified material weaknesses in its internal control over financial reporting related to the control environment and control activities.
• Cytek is implementing a remediation plan to address these weaknesses, including augmenting the workforce, revising control designs, and strengthening IT general controls.
• The company's strategy includes accelerating adoption of its solutions, continuing innovation, investing in integrated workflow solutions, and driving clinical research application development.
• The company relies on a mix of direct sales and distributor partnerships, with direct sales accounting for 75% of total revenue in 2024.
• The company's products are used in academic and government institutions, pharmaceutical and biotechnology companies, and clinical research organizations.
• The company faces competition from established and emerging life sciences and in vitro diagnostics companies.
• The company is subject to ongoing regulatory obligations and review by the FDA and other regulatory bodies.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While revenue increased and losses decreased, material weaknesses in internal control and a competitive market temper the outlook.

Positives

• Revenue increased by 4% in FY2024, indicating continued market demand.
• Net loss decreased significantly, suggesting improved operational efficiency.
• Strong cash position provides financial flexibility for future investments.
• The company is taking steps to remediate material weaknesses in internal controls.
• The company's Northern Lights-CLC system is registered for clinical use in the European Union and China, opening new market opportunities.
• The company launched the Enhanced Small Particle (ESP) Detection Option for its Cytek Aurora and Northern Lights systems, expanding product capabilities.
• The company has a large base of peer-reviewed publications showcasing and validating the importance and application of our technology in academic and clinical research settings.

Negatives

• Material weaknesses in internal control over financial reporting were identified, requiring remediation efforts.
• The company experienced a net loss of $6.0 million in 2024.
• The company relies on single source suppliers and, in some cases, sole source suppliers, for certain components and materials used in our systems and may not be able to find replacements or immediately transition to alternative suppliers.
• The company is subject to governmental export controls and sanctions programs that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.

Risks

• The company's ability to accurately forecast customer demand and manage inventory could be negatively affected by many factors, many of which are beyond our control.
• The company's international operations and expansion of our international business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
• The company's business is dependent on adoption of our products by academic and government institutions, CROs, pharmaceutical companies and clinical laboratories for their research and development activities focused on cell analysis.
• The market for cell analysis technologies and life sciences tools, including flow cytometry, is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve and sustain profitability.
• The company's products may become subject to more onerous regulation by the U.S. Food and Drug Administration (the FDA) or other regulatory agencies in the future, which could increase our costs and delay or prevent sales of our products or commercialization of new products and product enhancements, thereby materially and adversely affecting our business, financial condition, results of operations and prospects.
• The company's failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to data privacy and security (including security incidents) could harm our business.

Future Outlook

The company expects to continue investing in research and development, commercial infrastructure, and global expansion to drive future growth. The company expects recurring revenue on an absolute basis to increase and become an increasingly important contributor to our revenue as our installed base expands.

Management Comments

• Management is committed to remediating the control deficiencies that constituted the above material weaknesses by continuing to enhance our internal control over financial reporting.
• Management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel.

Industry Context

Cytek operates in the competitive cell analysis and life sciences tools market, facing competition from established and emerging companies. The company's FSP technology aims to capture a greater share of the cell analysis market by offering high-resolution, high-content, and high-sensitivity cell analysis.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• The document does not provide specific comparisons to comparible companies, projects, and results.

Legal Proceedings

• On August 14, 2024, Beckman Coulter, Inc. sued the Company in federal court in the District of Delaware, alleging that the Company's Aurora flow cytometers, Aurora CS cell sorters, and Northern Lights and Northern Lights-CLC products infringe U.S. Patent Nos. 10,330,582 and 11,703,443, each titled Flow Cytometer.

Stakeholder Impact

• Shareholders may experience stock price volatility due to market conditions and company performance.
• Employees may be affected by changes in company strategy and remediation efforts.
• Customers may benefit from continued innovation and product enhancements.
• Suppliers may be impacted by changes in trade policies and supply chain disruptions.

Next Steps

• Continue to innovate and offer our customers best-in-class solutions.
• Invest in integrated workflow solutions to drive pull-through from our consumables and services.
• Drive clinical research application development.

Key Dates

Keywords

Cytek Biosciences, cell analysis, flow cytometry, revenue, internal control, financial results, FSP technology, Aurora, Northern Lights, reagents, instruments